| 0.72 0.013 (1.88%) | 10-28 15:12 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.02  |
1-year : | 1.23 |
| Resists | First : | 0.87 |
Second : | 1.05 |
| Pivot price | 0.78  |
|||
| Supports | First : | 0.57 |
Second : | 0.47 |
| MAs | MA(5) : | 0.71 |
MA(20) : | 0.77 |
| MA(100) : | 0.51 |
MA(250) : | 0.65 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 31.4 |
D(3) : | 29.8 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 2.52 | Low : | 0.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BCAB ] has closed above bottom band by 36.6%. Bollinger Bands are 105.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.8 - 0.81 | 0.81 - 0.81 |
| Low: | 0.69 - 0.7 | 0.7 - 0.7 |
| Close: | 0.7 - 0.71 | 0.71 - 0.71 |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Thu, 23 Oct 2025
BioAtla (NASDAQ: BCAB) Showcases ROR2 ADC Ozuriftamab Vedotin for HPV+ OPSCC at IPVS - Stock Titan
Mon, 20 Oct 2025
BioAtla reports promising early data for dual-CAB cancer therapy - Investing.com
Fri, 03 Oct 2025
Median OS 21.5 months: BioAtla presents mecbotamab vedotin data in 44 sarcoma patients at SITC - Stock Titan
Fri, 03 Oct 2025
BioAtla, Inc. to Present Clinical Data on AXL-Targeting ADC Mecbotamab Vedotin at SITC 2025 Annual Meeting - Quiver Quantitative
Fri, 03 Oct 2025
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 10.5 (%) |
| Held by Institutions | 28.6 (%) |
| Shares Short | 3,000 (K) |
| Shares Short P.Month | 4,310 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.29 |
| Profit Margin | 0 % |
| Operating Margin | -574.8 % |
| Return on Assets (ttm) | -82.6 % |
| Return on Equity (ttm) | -813.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.88 |
| Sales Per Share | 0.18 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -0.67 |
| PEG Ratio | 0 |
| Price to Book value | -2.61 |
| Price to Sales | 3.88 |
| Price to Cash Flow | -0.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|